(Q35057210)

6 August 2017

1 reference

title

The role of intravenous immunoglobulin in the treatment of multiple sclerosis (English)

1 reference

6 August 2017

author

Per Soelberg Sørensen

series ordinal

1

object named as

Per Soelberg Sorensen

0 references

publication date

1 February 2003

1 reference

Journal of the Neurological Sciences

6 August 2017

published in

1 reference

6 August 2017

volume

206

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

123-130

1 reference

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Intravenous immunoglobulin treatment in lower motor neuron disease associated with highly raised anti-GM1 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Immunoregulation in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Pathology and pathogenesis of demyelinating diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Promotion of endogenous remyelination in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Experimental strategies to promote central nervous system remyelination in multiple sclerosis: insights gained from the Theiler's virus model system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Remyelination by oligodendrocytes stimulated by antiserum to spinal cord

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Immunoglobulins promote remyelination in the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Immunoglobulins reactive with myelin basic protein promote CNS remyelination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Passage of intravenous immunoglobulin and interaction with the CNS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

First results of immunotherapy with immunoglobulin G in multiple sclerosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Intravenous gamma globulin in progressive MS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Combined immunoglobulin and azathioprine in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Intravenous immunoglobulin for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

High dose intravenous immunoglobulin does not improve abnormalities in the blood-brain barrier during acute relapse of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

IV immunoglobulin does not reverse established weakness in MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900343-X

10.1016/S0022-510X(02)00343-X

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference